Research and Markets: Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline Review, H1 2013

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013" report to their offering.

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris). Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Plaque Psoriasis (Psoriasis Vulgaris).

- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

The rest is here:
Research and Markets: Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013